Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,715 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission.
Parisio L, Settanni CR, Varca S, Laterza L, Lopetuso LR, Napolitano D, Schiavoni E, Turchini L, Fanali C, Alfieri N, Pizzoferrato M, Papa A, Pafundi PC, Armuzzi A, Gasbarrini A, Pugliese D, Scaldaferri F. Parisio L, et al. Among authors: gasbarrini a. J Gastrointestin Liver Dis. 2023 Dec 22;32(4):452-459. doi: 10.15403/jgld-5084. J Gastrointestin Liver Dis. 2023. PMID: 38147610 Free article.
Exploring the link: Porto-sinusoidal vascular disorder and inflammatory bowel disease - A comprehensive narrative review.
Pugliese N, Giuli L, Mastrorocco E, Santopaolo F, Marcozzi G, Bezzio C, Buono AD, Gabbiadini R, Gasbarrini A, Ponziani FR, Armuzzi A, Aghemo A. Pugliese N, et al. Among authors: gasbarrini a. Dig Liver Dis. 2023 Dec 2:S1590-8658(23)01039-3. doi: 10.1016/j.dld.2023.11.021. Online ahead of print. Dig Liver Dis. 2023. PMID: 38044225 Review.
Transition from intravenous to subcutaneous biological therapies in inflammatory bowel disease: An online survey of patients.
Napolitano D, Settanni CR, Parisio L, Orgiana N, Poscia A, Schiavoni E, Turchini L, Cascio AL, Germini F, Sblendorio E, Milani A, Patteril C, Laterza L, Lopetuso LR, Pugliese D, Papa A, Gasbarrini A, Scaldaferri F. Napolitano D, et al. Among authors: gasbarrini a. Indian J Gastroenterol. 2024 Feb;43(1):215-225. doi: 10.1007/s12664-023-01500-2. Epub 2024 Jan 20. Indian J Gastroenterol. 2024. PMID: 38244138
Assessment of small intestinal bacterial overgrowth and methane production in patients on chronic proton-pump inhibitor treatment: prevalence and role of rifaximin in its management in primary care.
DE Bastiani R, Lopetuso LR, DE Bastiani M, Bacchin P, Benedetto E, Boscariolo L, Caneve R, Chesani F, Chiumeo F, Civic Z, Dainese A, DE Polo M, Disclafani G, Grattagliano I, Mana O, Mancuso M, Mastronuzzi T, Pati A, Pirrotta E, Salandini M, Sanna G, Scoglio R, Severino P, Tosetti C, Turnava L, Zamparella M, Elisei W, Gasbarrini A, Tursi A. DE Bastiani R, et al. Among authors: gasbarrini a. Minerva Gastroenterol (Torino). 2023 Dec;69(4):523-528. doi: 10.23736/S2724-5985.21.03118-1. Epub 2023 Mar 21. Minerva Gastroenterol (Torino). 2023. PMID: 36943203
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KG, Shipitofsky N, Zhang H, Wilson R, Han C, Feagan BG, Sandborn WJ, Panés J, Hisamatsu T, Lichtenstein GR, Sands BE, Dignass A; QUASAR Study Group. Peyrin-Biroulet L, et al. Gastroenterology. 2023 Dec;165(6):1443-1457. doi: 10.1053/j.gastro.2023.08.038. Epub 2023 Sep 1. Gastroenterology. 2023. PMID: 37659673 Free article. Clinical Trial.
Poliprotect vs Omeprazole in the Relief of Heartburn, Epigastric Pain, and Burning in Patients Without Erosive Esophagitis and Gastroduodenal Lesions: A Randomized, Controlled Trial.
Corazziari ES, Gasbarrini A, D'Alba L, D'Ovidio V, Riggio O, Passaretti S, Annibale B, Cicala M, Repici A, Bassotti G, Ciacci C, Di Sabatino A, Neri M, Bragazzi MC, Ribichini E, Radocchia G, Iovino P, Marazzato M, Schippa S, Badiali D. Corazziari ES, et al. Among authors: gasbarrini a. Am J Gastroenterol. 2023 Nov 1;118(11):2014-2024. doi: 10.14309/ajg.0000000000002360. Epub 2023 Jun 13. Am J Gastroenterol. 2023. PMID: 37307528 Free PMC article. Clinical Trial.
Histamine-producing bacteria and their role in gastrointestinal disorders.
Fiorani M, Del Vecchio LE, Dargenio P, Kaitsas F, Rozera T, Porcari S, Gasbarrini A, Cammarota G, Ianiro G. Fiorani M, et al. Among authors: gasbarrini a. Expert Rev Gastroenterol Hepatol. 2023 Jul-Dec;17(7):709-718. doi: 10.1080/17474124.2023.2230865. Epub 2023 Jul 6. Expert Rev Gastroenterol Hepatol. 2023. PMID: 37394958 Review.
Mortality risk according to different clinical characteristics of first episode of liver decompensation in cirrhotic patients: a nationwide, prospective, 3-year follow-up study in Italy.
Bruno S, Saibeni S, Bagnardi V, Vandelli C, De Luca M, Felder M, Fracanzani AL, Prisco C, Vitaliani G, Simone L, Gaeta GB, Stanzione M, Persico M, Furlan C, Stroffolini T, Salerno F, Maisonneuve P, Almasio PL; AISF (Italian Association for the Study of the Liver) – EPA-SCO Collaborative Study Group. Bruno S, et al. Am J Gastroenterol. 2013 Jul;108(7):1112-22. doi: 10.1038/ajg.2013.110. Epub 2013 Jun 4. Am J Gastroenterol. 2013. PMID: 23732467 Free article.
1,715 results